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Abstract.  The tyrosine phosphorylation sites in the 
human cxPDGF receptor (otPDGFR) required for as- 
sociation with PI-3 kinase have been identified as tyro- 
sines 731 and 742.  Mutation of either tyrosine sub- 
stantially reduced PDGF-induced PI-3 kinase activity 
but did not impair the receptor-mediated mitogenic re- 
sponse. We sought to determine whether PDGF- 
induced PI-3 kinase activity could be further ablated 
so as to exclude a low threshold requirement for 
PDGFR signal transduction.  Thus,  we mutated both 
tyrosine 731 and 742 and expressed the double mutant 
(Y731F/Y742F) in 32D hematopoietic cells. In such 
transfectants,  PDGF induced no detectable receptor- 
associated or anti-P-Tyr recoverable PI-3 kinase activ- 
ity.  Under the same conditions,  neither mobility shift 
of raf-1  nor tyrosine phosphorylation of either PLC7 
or MAP kinase was impaired.  32D transfectants ex- 
pressing the double mutant showed wild-type 
o~PDGFR levels of mitogenic and chemotactic re- 
sponses to PDGE To examine the effect of the double 
mutation in cells that normally respond to PDGF, we 
generated chimeras in which the cytoplasmic domains 
of wild-type otPDGFR, Y731F, and Y731F/Y742F 
were linked to the extracellular domain of colony- 
stimulating factor-1  (CSF-1) receptor (fms). After in- 
troduction of the chimeric receptors into mouse 
NIH/3T3 fibroblasts, the ability of CSF-1  to stimulate 
growth of these transfectants was examined.  Our data 
show that all these chimeric receptors exhibited simi- 
lar abilities to mediate CSF-l-stimulated call growth. 
These findings lead us to conclude that PDGF-induced 
PI-3 kinase activity is not required for PDGF- 
stimulated mitogenic pathway in both NIH/3T3 
fibroblasts and 32D hematopoietic cells. 
I 
NTERACTION of PDGF with its receptors causes activa- 
tion  of the receptor tyrosine kinase,  which leads to 
a cascade of biochemical events culminating  in mito- 
genesis (Williams,  1989).  Two PDGF receptor (PDGFR)  ~ 
genes, designated  c~ and ~, encode related proteins that can 
act independently to perform major PDGF signaling  func- 
tions, including proliferation  and chemotaxis (Matsui et al., 
1989).  Several  cetlular proteins,  including  phospholipase 
C3, (PLC3,),  GTPase-activating  protein (GAP), and phos- 
phatidylinositol-3  (PI-3) ldnase become associated with and 
tyrosine-phosphorylated by the activated  PDGFR (Meisen- 
helder et al., 1989; Molloy et al., 1989; Kaplan et al., 1990; 
Morrison et al., 1990; Kumjian et ai., 1989; Coughlin et al., 
1989; Kavanaugh et al., 1992). These interactions  are medi- 
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ated by high  affinity binding  between the src homology 2 
(SH2) domains of the substrates and specific phosphorylated 
tyrosine residues of receptor (Canfley et al.,  1991). For ex- 
ample, in the human flPDGFR, phosphorylation of tyrosine 
771 is necessary for association with GAP (Kashishian et al., 
1992; Kazlauskas et al., 1992). In contrast, phosphorylation 
of tyrosine 1021 in the carboxy-terminal  region is required 
for binding of PLC7 (Valius et al., 1993), while PI-3 kinase 
interaction  sites are tyrosine 740 and tyrosine 751 (Kashi- 
shian et al.,  1992; Kazlauskas  et al.,  1992). 
PI-3 kinase phosphorylates the inositol ring of PI, PI-4P, 
and PI-4,5P2 at the D3 position (Auger et al.,  1989; Whit- 
man et al.,  1988). Purification  of PI-3 kinase revealed that 
it consists of an 85-kD (p85) regulatory and a llO-kD (pll0) 
catalytic  subunit  (Skolnik  et al.,  1991; Escobedo et  ai., 
1991; Ostu et al., 1991; Hiles et ai., 1992). The p85 subunit 
lacks PI-3 kinase activity and functions as a regulator, which 
binds  to  the  activated  tyrosine kinase  (Hu et  al.,  1992; 
McGlade et al., 1992). Although the precise role of PI-3 ki- 
nase in regulating  cell growth remains unknown,  evidence 
that transforming  p60  v-s~ and polyoma middle-T mutants in- 
variably show associated PI-3 kinase activity has suggested 
that this enzyme may be necessary for mitogenic signaling 
(Fukui and Hanafusa,  1989). 
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sine 742  substantially impairs PDGF-induced PI-3 kinase 
activity, but not PDGF-stimulated mitogenesis in 32D cells 
(Yu et al.,  1991). Similar results have been observed using 
analogous mutants of the/3PDGFR in epithelial cells (Fantl 
et al., 1992). These results have implied that PDGF-induced 
PI-3 kinase is not required for mitogenic signal transduction. 
However,  we could not exclude the possibility that the low 
levels (--5-15 %) of residual PDGF-induced PI-3 kinase ac- 
tivity observed with such mutants were sufficient to trans- 
duce the PDGF mitogenic signal. In addition, neither the 
hematopoietic nor epithelial cell lines used in these investi- 
gations represented a physiological system for PDGF signal- 
ing because they do not normally express PDGFRs. To better 
define the role of PI-3 kinase in aPDGFR signal transduc- 
tion, we generated a double mutant (Y731F/Y742F) by sub- 
stituting phenylalanines for tyrosines 731 and 742 within the 
c~PDGFR. The present studies describe the effects of these 
mutations  on  PDGF-induced  PI-3  kinase  activity,  other 
downstream signaling molecules, as well as biological func- 
tions of the c~PDGFR in two different cell systems. 
Materials and Methods 
Site-directed Mutagenesis and Generation of 
fms/aPDGFR Chimeras 
Construction of the single mutant Y731F clone has been described previ- 
ously (Yu et al.,  1991). To generate the double mutant, an MI3 subclone 
containing the cytoplasmic region of the Y731F was used as a template, and 
an  oligonucleotide  (5tACTACACAGTTTGTCCCCAT-3~  encompassing 
tyrosine 742 of  human c~PDGFR was used to direct mntagenesis. The muta- 
genesis reaction was performed according to the manufacturer's protocol 
("Mutagene M13 in vitro mutagenesis'; Bio Rad Laboratories, Hercules, 
CA). The entire mutant c~PDGFR cDNA was then subcloned into the LTR-2 
eucaryotic expression vector (Di Fiore et ai.,  1987a). 
To generate fms/aPDGFR chimeras, the SalI-PvuII fragment of human 
CSF-1R (fms) extracellular domain and PvuII-BamHI fragment of the cyto- 
plasmic domain ofwt t~PDGFR, Y731F and Y731F/Y742F were ligated to 
the LTR-2  expression vector digested with Xhol and BarnHI (Di Fiore et 
al.,  1987a). 
Transfection and Cotransfection Assays 
DNA transfection of 32D cells was performed by the electroporation proce- 
dure (Pierce et al., 1988).  Mass populations of stably transfected cells were 
selected by their ability to survive in growth medium containing myco- 
phenolic acid (80 raM). Transfection of NIH/3T3 cells was performed by 
the calcium phosphate precipitation technique,  as previously described 
(Heidaran et al.,  1990).  To analyze the effects of increased wild-type (wt) 
or mutant aPDGFR expression on PDGF-A-transforming efficiency,  co- 
transfection of o~PDGFR, and PDGF-A expression cDNAs was performed 
using  similar amounts  (,~1  #g)  of each construct.  Since PDGF-A and 
otPDGFR construct each contain different drug-resistant markers (Beck- 
mann et al., 1988;  Di Fiore et ai., 1987a),  the number of cells expressing 
both cDNAs was determined by measuring the number of colonies that sur- 
vived in the presence of both mycophenolic acid (80 mM) and geneticin 
(750 ttg/mi). The number of transformed foci was determined 2-3 wk after 
transfection in plates that did not undergo any marker selection. For mea- 
suring the colony-stimulating factor-1 (CSF-1)-dependent  transformation of 
NIH/3T3 expressing  fms/otR chimeras, cells were transfected as described 
above. After 5 d, cell cultures were maintained in DME containing 2 % calf 
serum supplemented with or without human CSF-I (100 ng/ml). 
Iramunoblot and Immunoprecipitation Analyses 
32D cells were washed twice in DME and incubated at 37°C for 2 h  in 
serum-free medium. The quiescent 32D cells were then stimulated with 
PDGF-AA (Upstate Biotechnology, Inc., Lake Placid, NY) (100 ng/mi) for 
5 rain at 37°C followed by treatment with 5 mM diisopropyl fluorophos- 
phate (DFP) at 4"C for 5 rain. Cell lysis was performed using 1 rni of P-'l~yr 
iysing buffer containing 50 mM Hepes (pH 7.5),  1% Triton X-100, 50 mM 
NaC1, 50 mM NaF, 10 mM sodium pyrophosphate, 5 mM EDTA,  1 mM 
Na3VO4,  1 mM PMSF,  10 ~g/mi aprotinin,  10/zg/mi leupeptin, and 5 
mM DFP/5  x  107 cells. Clarified lysates (100/~g/lane) were resolved by 
8%  SDS-PAGE followed by  immunoblotring with the appropriate anti- 
serum. Polyclonal antipeptide serum against amino acids 959-973  of the 
human ~PDGFR has been described (Heidaran et al.,  1991; Yu et al., 
1991).  This antibody recognizes both the human and murine c~PDGFR 
equally well. Monoclonal anti-P-Tyr was obtained from Upstate Biotech- 
nology, Inc., and polyclonal anti-raJ:l serum was raised against a peptide 
CTLTTSPRLPVF encompassing the carboxy terminal domain of the hu- 
man raf-1 (Gntkind, J. S., N. Xu, and K. C. Robbins, personal communi- 
cation). 
For immunoprecipitation, cells were lysed as described above. Around 
2 mg of soluble lysate was immunoprecipitated with anti-P-Tyr antibody 
(Upstate Biotechnology, Inc.). Immunoprecipitates were resolved on SDS- 
PAGE and immunoblotted with monoelonal anti-PLC~/(Upstate Biotech- 
nology, Inc.) or monoclonal anti-MAP kinase (Zymed Laboratories, Inc., 
South San Francisco, CA). 
For lysing NIH/3T3 cells, the same lysing buffer lacking 5 mM DFP was 
used.  Clarified lysates were  subjected to  immunoprecipitation using a 
monoclonai antibody against human ctPDGFR that recognizes human, but 
not murine txPDGFR (Yu et ai.,  1994).  After SDS-PAGE and electroblot- 
ring, the filter was immunoblotted with a polyclonai anti-t~PDGFR antise- 
rum, which reacts with both human and murine c~PDGFR equally well (Yu 
et al.,  1991). 
PI-3 Kinase Assay 
For measurement of  in vivo uPDGFR-associated PI-3 kinase activity, quies- 
cent 32D ceils were exposed to PDGF-AA (100 ng/ml) for 5 rain at 37°C, 
incubated with 5 mM DFP at 4"C for 5 min, and lysed in a buffer containing 
20 mM Tris (pH 8),  137 mM NaCI, 2.7 mM KCI,  1 mM MgCI2,  1 mM 
CaCI2,  1%  Nonidet P-40,  10%  glycerol, 1 mM Na3VO4, 5  mM DFP,  1 
mM PMSF, and 10 ttg/rnl aprotinin and leupeptin. Soluble lysates (2 mg) 
were immunoprecipitated with monoclonal anti-c~PDGFR  antibody (Gen- 
zyme Corp., Boston, MA) or anti-P-Tyr antibody (Upstate Biotechnology, 
Inc.). Immunoprecipitates were recovered with protein G-Sepharose and 
assayed for PI-3 kinase activity as measured by their ability to phosphory- 
late PI to yield PIP (Gutkind et al.,  1990). 
Mitogenesis and Chemotaxis Assays 
For measurement of DNA synthesis, cells were washed twice with PBS and 
plated at 3  x  105 cells/mi into 24-well plates (Costar Corp., Cambridge, 
MA) in RPMI-1640 medium containing 15 % fetal calf serum in the absence 
or presence of increasing concentrations of  PDGF-AA or murine 1I.,-3 (Gen- 
zyme Corp.) for 24 h followed by labeling with 5/~Ci/ml of [3H]thymidine 
for  5  h.  Cells  were  harvested  and  processed  for  measurement  of 
[3H]thymidine incorporation,  as previously described (Heidaran  et  al., 
1991; Matsui et ai., 1989).  For determination of directed cell migration in 
response to PDGF-BB, modified Boyden chambers and Nucleopore filters 
(5-~m pore size; Costar Corp.) were used as described before (Heidaran 
et al.,  1991; Matsui et al.,  1989). 
Sofl Agar Assay 
For analysis of proliferation in semisolid medium,  1  x  105 of NIH/3T3 
transfected ceils were suspended in 0.4% agarose (SeaPlaque; FMC Bio- 
Products, Rockland, ME) in DME containing 10% caif serum as described 
elsewhere (Di Fiore et al.,  1987a).  Cells were fed with DME containing 
10% calf serum in the presence or absence of 100 ng/ml of human CSF-1 
once per week. Colonies were stained with p-iodonitrotetrazolium violet 
(Sigma Immunochemicals, St. Louis, MO) and scored after 2 wk. 
Results 
Effects of  Double Mutations on PDGF-induced PI-3 
Kinase Activity 
We have previously shown that mutation of tyrosine 731 or 
742 within the kinase insert domain of the otPDGFR impairs 
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respectively (Yu et al.,  1991).  In an effort to further ablate 
t~PDGFR-asssociated PI-3 kinase activity, we generated a 
double mutant ctPDGFR (Y73 IF/Y742F), and cloned it into 
a  long terminal repeat-driven expression vector (Di Fiore 
et al., 1987a). To analyze the double mutant, 32D cells were 
transfected by electroporation, and mass populations were 
marker selected.  The level of expression of wt or mutant 
aPDGFR in independent 32D transfectants was found to be 
similar,  ,o5  x  10' receptors/cell (Matsui et al.,  1989,  and 
data not shown). To assess the effects of the Y731F/Y742F 
mutant on PDGF-induced PI-3 kinase activity, cell lysates 
from PDGF-stimulated or unstimulated  32D transfectants 
were immunoprecipitated with a monoclonal anti-aPDGFR 
antibody. The immune complexes were subjected to an in 
vitro PI-3 kinase assay (Gutkind et al.,  1990). 
As shown in Fig. 1 A, addition of PDGF caused >50-fold 
increase in phosphatidylinositol phosphate (PIP) formation 
Figure 1.  Comparison  of PDGF-induced  receptor-associated  or 
anti-P-Tyr recoverable PI-3 kinase activities in PDGF-stimulated 
32D transfectants. 32D cells (lanes 1 and 2) or 32D cells expressing 
wt  aPDGFR  (lanes  3  and  4),  Y731F (lanes  5  and  6),  or 
Y73 IF/Y742F (lanes 7 and 8) were either untreated (-) or treated 
(+) with PDGF-AA. Cell lysates were immunoprecipitated with a 
monoclonal antibody directed against aPDGFR (A) or anti-P-Tyr 
(C). Immune complexes were then subjected to the PI-3 kinase as- 
say described before (Gutkind et al., 1990). The PI-3 kinase reac- 
tion products were then analyzed by thin-layer chromatography. 
The positions of phosphatidylinositol phosphate (PIP) and the ori- 
gin (Or/) are designated by arrows. Fractions of anti-o~PDGFR im- 
mune complex were immunoblotted with a polyclonal antiserum 
against carboxy terminus of human txPDGFR (B). 
in PDGFR immunoprecipitates from 32D cells expressing 
the wt t~PDGFR (Fig.  1 A, lanes 3 and 4).  As previously 
reported (Yu et al., 1991), the PI-3 kinase activity associated 
with the Y731F upon PDGF triggering was ~5-10% of that 
associated with the wt receptor (Fig.  1 A, lanes 5 and 6). 
Under  the  same  conditions,  32D  cells  expressing  the 
Y731F/Y742F  receptor showed no detectable increase in 
PIP level upon PDGF triggering (Fig.  1 A, lanes  7 and 8). 
As a control, a portion of each preparation of immunoprecip- 
itated receptors was resolved by SDS-PAGE and immuno- 
blotted with anti-ctPDGFR antiserum. The levels of recep- 
tors among the preparations varied less than twofold (Fig. 
1B). 
PI-3 kinase activity has also been observed in anti-P-Tyr 
immunoprecipitates after ligand stimulation (Auger et al., 
1989; Kaplan et al.,  1987). Moreover, the p85 subunit has 
been  shown  to  be  tyrosine-phosphorylated  in  PDGF- 
triggered cells (Kavanaugh et al.,  1992). Thus, we also per- 
formed PI-3 kinase assays using anti-P-Tyr immune com- 
plexes after PDGF stimulation.  As shown in Fig.  1 C,  the 
Y731F mutant showed --5 % ofwt o~PDGFR levels of  anti-P- 
Tyr recoverable PI-3 kinase activity (Fig.  1 C, lanes 5 and 
6),  while the double mutant resulted in  complete loss of 
recoverable activity (Fig.  1 C, lanes  7 and 8). Anti-P-Tyr 
immune  complexes  from  cells  expressing  wt  or  mutant 
aPDGFRs were resolved by SDS-PAGE and immunoblotted 
with polyclonal anti-p85  antibody.  Consistently,  cells ex- 
pressing o~PDGFR  (Y731F/Y742F) showed no increase in 
anti-P-Tyr recovery of p85 upon PDGF stimulation, while 
cells expressing the Y731F mutant showed a low but detect- 
able level of anti-P-Tyr recovery of p85 as compared to that 
ofwt c~PDGFR (data not shown). All of  these results confirm 
that mutations affecting both tyrosines 731 and 742 resulted 
in complete loss of PDGF-stimulated receptor-associated or 
anti-P-Tyr recoverable PI-3 kinase activity. 
Effects of ~rosine Mutations on PDGF-stimulated 
Activation of Other Cellular Signaling Molecules 
To study the effects ofthe mutations on receptor interactions 
with other signaling molecules, we analyzed PDGF-stimu- 
lated  tyrosine  phosphorylation  of  PLC3,  and  mitogen- 
activated protein (MAP) kinase as well as activation of raf-1. 
Accordingly, cell lysates of PDGF-treated or untreated 32D 
transfectants were immunoprecipitated with anti-P-Tyr fol- 
lowed by immunoblotting with PLC3, monoclonal antibody. 
The levels of expression and  tyrosine phosphorylation of 
aPDGFRs upon triggering were similar among the transfec- 
tants analyzed (Fig. 2, A and B). Fig. 2 C shows that PLC'y 
was tyrosine-phosphorylated at comparable levels in PDGF- 
stimulated cells expressing wt or mutant receptors (Fig. 2 C, 
lanes 4, 6, and 8). These results imply that mutation of nei- 
ther Y731 nor Y731/Y742 impaired in vivo kinase activity 
of the txPDGFR for this well-characterized substrate. Such 
results are consistent with recent findings that the tyrosine 
required for/3PDGFR to associate with PLC't is tyrosine 
1021  within  its  carboxy-terminal domain  (Valius  et  al., 
1993). 
Both raf-1 and MAP kinase are cytoplasmic serine/threo- 
nine protein kinases that are indirectly activated in response 
to PDGF (Morrison et al.,  1989;  I.~llemain et al.,  1991; 
Pelech and Sanghera,  1992). The raf-1 protein kinase is re- 
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stream signal molecules in PDGF-stimulated 32D transfectants. 
32D cells (lanes I and 2) or 32D ceils transfected with wt c~PDGFR 
(lanes 3 and 4), Y731F (lanes 5 and 6), or Y731F/Y742F (lanes 
7 and 8) were either untreated (-) or treated (+) with 100 ng/ml 
of PDGF-AA. Clarified lysates (100 /zg/lane) were resolved by 
SDS-PAGE and transferred to Immobilon-P (Millipore). The trans- 
ferred blot was  immunoprobed  with  anti-c~PDGFR serum  (A), 
monoclonal anti-P-Tyr antibody (B), or polyclonal anti-raf-1 an- 
tiserum (D). In C and E, 2 mg of clarified lysates were subjected 
to  immunoprecipitation  using  anti-P-Tyr  antibody  followed by 
SDS-PAGE. The transferred blot was immunoblotted with anti- 
PLC7 antibody (C) or monoelonal anti-MAP kinase antibody (E). 
quired  for proliferation of NIH/3T3  ceils  (Kolch et  al., 
1991), and it has been reported to be upstream of MAP ki- 
nase (Kyriakis et al.,  1992; Howe et al.,  1992), which can 
activate c-jun by specific phosphorylation of two serine sites 
within  c-jun  (Pulverer et al.,  1991).  Therefore, raf-1 and 
MAP  kinases  seem  to  play  important  roles  in  PDGF- 
stimulated mitogenic signaling. To investigate the effects of 
Y731F and/or Y731F/Y742F receptor mutations on PDGF- 
stimulated activation of raf-1, we studied the mobility shift 
of this kinase as it was used as an index of its activation. Ac- 
cordingly, total cell lysates from PDGF-triggered 32D trans- 
fectants were resolved by SDS-PAGE and immunoblotted 
with antiserum against mill. As shown in Fig. 2 D, wt and 
each of the mutant receptors caused a similar raf-1 mobility 
shift upon PDGF stimulation (lanes 3-8). 
We further tested the effects of the same mutations on 
PDGF-induced tyrosine phosphorylation of MAP  kinase. 
Accordingly, anti-P-Tyr immune complexes from 32D trans- 
fectants were resolved by SDS-PAGE and then immunoblot- 
ted with monoclonal anti-MAP kinase antibody.  Fig.  2  E 
shows that neither Y731F nor Y731F/Y742F mutant recep- 
tors impaired PDGF-stimulated tyrosine phosphorylation of 
MAP kinase (Fig.  2  E,  lanes 3-8).  Since tyrosine phos- 
phorylation of MAP kinase correlates well with and is re- 
quired for its activation (Anderson et al.,  1990; Pelech and 
Sanghera,  1992),  these  data  further  suggest  that  neither 
Y731F nor Y731F/Y742F mutations impaired the ability of 
the aPDGFR to cause activation of MAP kinase in response 
to PDGF. 
Mitogenic and Chemotactic Responses of  Mutant 
,PDGFRs in 32D Cells 
Expression of PDGFRs  in IL-3-dependent 32D cells has 
previously been shown to allow efficient coupling with intra- 
cellular pathways of mitogenic and chemotactic signaling 
(Matsui et al., 1989). To test the biological effects of  the dou- 
ble mutant in 32D cells, we compared mitogenic activation 
by wt and mutant otPDGFRs. As shown in Fig. 3 A, PDGF 
induced  a  dose-dependent  increase  in  DNA  synthesis  in 
32D  transfectants  containing  either  wt  or  double-mutant 
o~PDGFRs with ~10-20 rig/m1 required for half maximal re- 
sponses. Moreover, the maximal stimulation in DNA synthe- 
sis observed with 32D cells expressing the Y731F/Y742F 
receptor was similar to that of transfectants expressing the 
wt receptor (Fig.  3 A). Thus, despite complete abrogation 
of PDGF-induced receptor-associated or anti-P-Tyr recov- 
erable PI-3 kinase activity, the double mutation was not as- 
sociated with any significant reduction in mitogenic signal- 
ing in 32D cells. 
Chemotaxis is another major biological response medi- 
ated by ,PDGFR in 32D cells (Matsui et al.,  1989). Thus, 
we also compared the chemotactic responsiveness of trans- 
fectants containing wt and mutant ,PDGFRs. AS shown in 
Fig. 3 B, cells expressing the wt oePDGFR exhibited an eight- 
fold increase in chemotactic response to PDGF (100 rig/m1). 
32D cells expressing the mutant o~PDGFR (Y731F/Y742F) 
demonstrated a  comparable fold increase under the same 
conditions.  Thus,  despite  complete  inhibition  of PDGF- 
induced PI-3 ldnase activity, the Y731/Y742 mutant showed 
no impairment in either mitogenic or chemotactic responses 
to PDGF in 32D cells. 
Comparison of  the Transforming Activity of wt 
and Mutant ~PDGFR in NIH/3T3 Cells Cotransfected 
with PDGF-A Chain 
We next sought to investigate the effect of the Y731/Y742 
mutation in a cell type, NIH/3T3, which normally expresses 
PDGFRs. To do so, we used a PDGF-A chain transformation 
enhancement assay (Heidaran et al.,  unpublished results). 
PDGF-A  chain  is  known  to  exhibit  low  transforming 
efficiency as compared to PDGF-B chain in NIH/3T3 cells, 
which  express  both  c~  and  /~PDGFRs  (Beclanann  et  al., 
1988). aPDGFR levels have been shown to be limiting for 
PDGF-A chain transformation, since cotransfection of con- 
structs expressing PDGF-A and the wt o~PDGFR results in 
increased PDGF-A-transformed foci. 
As shown in Fig. 4 A, transfection with PDGF-A resulted 
in ,~20 transformed foci/pg (Fig. 4 Aa). In contrast, cotrans- 
fection of PDGF-A chain with the wt c~PDGFR resulted in 
,,0200  foci/~g of PDGF-A chain (Fig. 4 Ab). It can be ob- 
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Figure 3. Comparison of PDGF-induced mitogenic and chemotac- 
tic response of 32D transfectants. DNA synthesis of 32D cell ex- 
pressing wt aPDGFR (4), Y731F (O), or Y731F/Y742F (11) was 
measured by pH]thymidine incorporation in IL-3-free medium as 
described in Materials and Methods (A). Each point represents the 
mean value of duplicate samples. ChemotaXis was determined by 
directed ceil migration in response to 100 ng/ml of PDGF-BB (B). 
Modified Boyden  chambers and Nncleopore filters (5-ttm pore size) 
were used in this assay. Similar results were obtained in three inde- 
pendent experiments. 
served  that  cotr~msfeetion with  either  Y731F  or  Y731F/ 
Y742F caused a similar enhancement in PDGF-A focus in- 
duction to that observed with the wt receptor (Fig. 4 A, c 
and d). As a control, PDGF-A cotransfection with a mutant 
otPDGFR (K627R), which contains a mutation in the ATP- 
binding site, led to only *20 foei (Fig. 4 Ae). To ensure that 
the  lack  of increase  in  transforming  activity of PDGF-A 
coexpressed with K627R receptor was not caused by lower 
level of expression of the mutant receptor, we examined the 
human oePDGFR levels expressed in each coselected culture. 
Accordingly, total cell lysates (2 mg) were subjected to im- 
munoprecipitation using a monoelonal antibody that recog- 
nizes human but not the endogenous oLPDGFR. The immune 
complexes were then subjected to immunoblot analysis using 
a polyclonal antibody to the o~PDGFR. Results shown in Fig. 
4 B indicate that the expression level of  ectopically expressed 
otPDGFR among these cultures is comparable. Table I sum- 
Figure 4.  Comparison of the ability of wt and mutant aPDGFRs 
to enhance PDGF-A-transforming function in NIH3T3. NIH/3T3 
cells were cotransfected with PDGF-A chain and LTR-gpt marker 
(Aa),  wt  aPDGFR  (Ab),  Y731F  (Ac),  Y731F/Y742F  (Ad),  or 
K627R (Ae). Transforming loci were detected 3 wk after transfec- 
tion. Ceils were fixed with 70% ethanol and stained with Giemsa 
stain. (B) The level of  human c~PDGFR expressed in each transfec- 
tant was analyzed. Cell lysates from marker-selected cultures were 
subjected to immunoprecipitation  using monoclonal  anti-aPDGFR 
antibody that recognizes human but not the murine aPDGFR. Af- 
ter SDS-PAGE and electroblotting, the filter was immunoblotted 
with a polyclonai anti-c~PDGFR antiserum. 
marizes the results of several independent experiments in 
which we measured enhancement Of PDGF-A-transforming 
activity coexpressed with various cxPDGFR constructs. Our 
results show that wt aPDGFR, Y731F and Y731F/Y742F all 
enhance PDGF-A-transforming activity to a similar level, as 
determined by the number of transformed loci/number of 
marker-selected colonies. Under the same conditions, trans- 
fection with the receptor constructs alone did not lead to any 
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Transforming Activity of PDGF-A Chain 
No. of transformed foci/ 
no. of marker-selected  colonies 
Trans-  Trans-  Trans- 
DNA transfected  fection 1  fection 2  fection 3 
PDGF-A +  LTR-gpt  4/40  30/500  30/200 
PDGF-A +  WT  40/20  300/300  100/50 
PDGF-A +  Y731F  100/100  300/300  150/80 
PDGF-A +  Y731F/Y742F  20/10  150/100  50/30 
PDGF-A +  K627R  4/20  20/200  30/200 
Transfection  was performed  by the calcium-phosphate  precipitation  method,  using 
1 p.g of PDGF-A eDNA, 1 #g of indicated ctPDGFR  eDNA, and 40/~g of calf 
thymus DNA as carrier. Focus formation  was scored 14-21 d after  transfection 
in unselected cultures. To measure the number  of cotransfected  cells, marker 
selection was performed  in paralleled cultures using medium  containing both 
mycophenolic acid (80 mM) and geneticin (750 t~g/ml). Colonies surviving 
double-marker selection were scored 14-21 d after transfection. 
cellular transformation (data not shown). Thus, all of these 
results indicate that tyrosine mutations that specifically abro- 
gate PDGF-induced PI-3 kinase activity do not impair the 
ability of the ctPDGFR to enhance PDGF-A chain transfor- 
mation of fibroblasts.  In this  cotransfection assay,  we ob- 
served  that  the  number of transformed foci exceeded  the 
number of marker-selected colonies when PDGF-A-trans- 
forming activity was greatly enhanced.  This may be caused 
by the differences in threshold levels of proteins required for 
forming foci and for surviving double-marker selection. AI- 
teruatively, it may result from the different levels of expres- 
sion of transfected ligand and receptor vs that of marker- 
resistent genes, since they are driven by different promoters 
(Beckmann et al.,  1988;  Di Fiore et al.,  1987a). 
CSF-l-stimulated Cell Growth of NIH/3T3 
Cells Transfected with Chimera Containing the 
Extracellular Domain of  fms and the Cytoplasmic 
Domain of wt and Mutant ~PDGFR 
Since endogenous aPDGFR in NIH/3T3 cells may be acti- 
vated in the PDGF-A cotransfection assay, we generated chi- 
meric receptors between the extracellular domain of  fins and 
the  cytoplasmic  domains  of  wt  oePDGFR,  Y731E  and 
Y731F/742F (Fig. 5 A). The chimeric receptors (designated 
as fms/t~RWT, fms/ctR731,  and fms/etR731+742,  respec- 
tively) were transfected into NIH/3T3 cells,  which do not 
normally expressfms. Cell lysates of NIH/3T3 transfectants 
treated with or without CSF-1  were resolved by SDS-PAGE 
and immunoblotted with either anti-aPDGFR serum against 
carboxy-terminal domain of t~PDGFR (Yu et al.,  1991) or 
anti-P-Tyr. As shown in Fig. 5 B, anti-otPDGFR serum de- 
tected 170-kD chimeric receptors (lanes 2-4), as well as the 
endogenous 180 kD aPDGFR (lanes 1-4). The intensity of 
the receptor signal derived from chimeras was comparable 
to that from endogenous o~PDGFR, which is expressed at 6.5 
×  l@/cell  (Heidaran et al.,  1993).  CSF-1  stimulation in- 
duced tyrosine phosphorylation of the  170-kD protein spe- 
cies, but not the  180-kD species (Fig. 5  C, lanes 4,  6,  and 
8),  suggesting endogenous c~PDGFRs are not cross-phos- 
phorylated by activated chimeric receptors.  Since  the  ex- 
pression level of fms/otR731  and fms/c~R731+742 were ap- 
proximately three- and twofold that off  ms/erR, respectively, 
the tyrosine phosphorylation level among each chimera was 
Figure  5.  Expression  and  tyrosine-phosphorylation  of  fins/ 
~PDGFR  chimeric  receptors.  (A)  Schematic  diagram  of  wt 
otPDGFR, fins, and chimeric receptors between  fens and o~PDGFRs. 
Coding  regions of the c~PDGFR are represented  by open boxes. 
Coding regions offms are represented by shaded boxes. Black boxes 
correspond  to signal peptide (SP) and transmembrane  (TM) do- 
mains.  The  number indicates  the  site  of mutated  tyrosines  of 
otPDGFR. (B) Total cell lysates of NIH/3T3 cells transfected with 
vector alone (lane I ),fms/aRWT (lane 2), fms/e~R731 (lane 3), and 
fms/t~R731+742 (lane 4) were resolved by SDS-PAGE and trans- 
ferred to immobilon-P. The membrane was immunoblotted  with 
anti-aPDGFR serum against the carboxy-terminal domain of the 
~PDGFR that recognizes both the human and murine  c~PDGFR 
equally well (C). Total cell lysates of NIH/3T3 stimulated or not 
with  CSF-1 were  resolved  by  SDS-PAGE,  and  transferred  to 
immobilon-P. The membrane was then immunoblotted with anti- 
P-Tyr. 
comparable after normalizing to their receptor level (Fig. 5, 
B and C). Under these conditions, NIH/3T3 cells expressing 
fms/otR731+742 showed no increase in anti-P-Tyr recovery 
of p85 upon CSF-1  stimulation,  while cells expressing the 
fms/aR731 mutant showed a low but detectable level of anti- 
P-Tyr recovery of p85  as  compared to  that of fms/c~RWT 
(data not shown). 
We next compared the ability of the chimeric receptors to 
mediate CSF-l-dependent growth of NIH/3T3 transfectants 
by soft agar assay (Pierce et al.,  1990).  Thus, the NIH/3T3 
transfectants were plated in a semisolid medium containing 
10%  calf serum supplemented with or without CSF-1.  As 
shown.in Fig. 6, NIH/3T3 transfectants failed to grow with- 
out CSF-1 stimulation (Fig. 6, A, C, E, and G). In contrast, 
NIH/3T3 transfected withfms/otPDGFR chimeras exhibited 
similar ability to form progressively growing colonies in the 
presence of CSF-1  (Fig. 6, D, F, and H). Under these condi- 
tions,  CSF-1  stimulation  did  not  induce  proliferation  of 
NIH/3T3 cells transfected with vector alone (Fig.  6, A and 
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of  NIH/3T3 Cells Expressing fms/~PDGFR 
Chimeric Receptors 
Soft agar growth (%) 
Plasmid  -  CSF-I  +  CSF-I 
LTR-gpt  1  1 
fms/~xRWT  6  48 
fms/t~R731  6  53 
fras/~xR731  +742  6  38 
Marker-selected  NIH/3T3  transfectants  (1  x  10  s) were suspended  in 0.4% 
semisolid agarose in the presence of DME supplemented with 10% calf serum. 
Cells were then fed with this media lacking or containing CSF-1 (100 ng/mi) 
once per week. The number represems the percentage of  the cells forming colonies 
of size >30 ~,m in diameter after 2 wk. Results represent mean values of dupli- 
cate plates. 
Figure 6.  Comparison  of the  CSF-l-stimulated  cell growth  of 
NIH/3T3 cells transfected with fms/c~PDGFR  chimeric receptors. 
N1H/3T3 cells transfected with vector alone (A and B), fms/o~RWT 
(C and D), fms/~R731 (E and F), and fms/~R731+742 (G and H) 
were suspended in 0.4% agarose diluted in DME supplemented 
with 10% calf serum as described in Materials and Methods. Cells 
were then fed with DME containin~ 10% calf  serum in the presence 
or absence of  CSF-1 (100  ng/ml) once per week. Photographs were 
taken by using light microscope after 2 wk. 
B). Table H summarizes the percentage of the cells forming 
progressively growing colonies after 2 wk of CSF-1 stimula- 
tion.  These  results  strongly  suggest  that  the  ability  of 
fms/txRWT to mediate CSF-l--dependent growth of NIH/3T3 
cell is comparable to that offms/otR731 or  fms/otR731+742. 
It  has  been  reported  that  overexpression of EGFR  in 
NIH/3T3 fibroblasts is sufficient for llgand-dependent trans- 
formation of these cells (Di Fiore et al.,  1987a).  Using a 
similar strategy, we sought to compare the ability of each 
fms/otPDGFR chimeras to mediate CSF-l-induced transfor- 
marion of NIH/3T3 fibroblasts. Accordingly, NIH/3T3 cells 
were transfeeted with the chimeric receptors or vector alone, 
and the cell cultures were maintained in DME containing 
2 % calf serum supplemented with or without human CSF-1 
(100 ng/ml). As shown in Table Ill, transfection with vector 
alone did not result in any detectable focus formation. How- 
ever,  transfection  with fms/c~RWT,  fms/aR731,  and fms/ 
c~R731+742 resulted in significant and similar level of focus 
formation in the presence of CSF-1.  Together, our findings 
clearly suggest that ligand-induced association of  PI-3 kinase 
activity with receptor is not necessary for ,PDGFR-medi- 
ated cell proliferation and transformation in a  physiologi- 
cally relevant cell system. 
Discussion 
Our present studies demonstrate that mutations of tyrosines 
731 and 742 within the kinase insert domain of  the otPDGFR 
(Y731F/Y742F) completely impaired PDGF-induced recep- 
tor-associated or anti-P-Tyr recoverable PI-3 kinase activity. 
Yet the mutation of these tyrosines did not affect the ligand- 
dependent  receptor  autophosphorylation,  tyrosine  phos- 
phorylation of PLC-% and MAP kinase or mobility shift of 
raf-1.  In 32D cells,  the ectopic expression of the mutant 
otPDGFR led  to ligand-dependent mitogenic and chemo- 
tactic responses that were comparable to that induced by the 
Table IlL Comparison of  the Ability of  fms/otPDGFR 
Chimeric Receptors to Mediate CSF-l-induced 
Transformation of  NIH/3T3 Cells 
No. of transformed  foci/ 
no. of marker-selected  colonies 
Plasmid  CSF-I  Transfection  1  Transfection  2 
LTR-gpt  -CSF-I  01500  0/500 
+CSF-1  01500  01500 
fms/cxRWT  -  CSF-  1  01500  01500 
+ CSF-  1  1501500  1001500 
fms/txR731  -  CSF-  1  0/500  1/500 
+CSF-I  1001500  100/500 
fmMtxR731 +742  -CSF-I  01500  01500 
+CSF-I  1001500  1001500 
NIH/3T3 cells transfection was performed by the calcium-phosphate precipita- 
tion method, using 1 t~g of indicated fmslaPDGFR chimeric receptor cDNA 
and 40 ~tg of calf thymus DNA as carrier.  Cells were grown in medium con- 
mining 2% calf sennn with or without  100 ng/ml of human CSF-I after 5 d 
after transfection. Focus formation was scored 2-3 wk after transfecfion. Madmr 
selection was performed  in medium cotttaining mycophenolic acid (80 raM). 
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the same ability as the wt ccPDGFR to enhance transforming 
activity of PDGF-A chain in NIH/3T3 cells. Furthermore, 
CSF-1 induced similar levels of cell growth and transforma- 
tion of NIH/3T3  cells transfected with chimeric receptor 
containing the extracellular domain offms and the cytoplas- 
mic domain of wt or mutant aPDGFRs.  Therefore, these 
results suggest that PDGF-induced PI-3 kinase activity is not 
necessary in o~PDGFR-mediated mitogenic, proliferative, or 
transforming signaling pathways. 
Previously, we have shown that mutation of tyrosine 731 
or 742 of the aPDGFR impaired PDGF-induced PI-3 kinase 
activity 95 % or 80 %, respectively, but not PDGF-stimulated 
mitogenesis in  32D  cells  (Yu  et  al.,  1991). Fantl  et  al. 
reported that similar mitogenic effects were observed using 
analogous single mutants of mouse/~PDGFR in normal mu- 
rine mammary gland (NMuMG) epithelial cells (Fantl et al., 
1992).  However, they found that mutation of both tyrosines 
of ~/PDGFR completely abrogated PDGF-induced PI-3 ki- 
nase activity and mitogenic response in that cell line (Fantl 
et al., 1992). These results suggest that a low level of PDGF- 
induced PI-3 kinase activity is required in PDGF mitogenic 
signaling. This is in contrast to our findings showing that 
complete abrogation of PDGF-induced PI-3 kinase activity 
does not impair PDGF-induced mitogenic response in 32D 
cells. To address this discrepancy, we used NIH/3T3 cell line 
since  it provides  a  biologically relevant system to  study 
c~PDGFR-mediated  signaling.  Using  chimeric  receptors 
containing the extracellular domain off  ms and the cytoplas- 
mic domains of wt c~PDGFR, Y73 IF, and Y731F/Y742F,  we 
showed that the ability of these chimeric receptors to medi- 
ate cell growth and transformation of NIH/3T3 cells induced 
by CSF-1 is similar. Sincefms is not expressed in NIH/3T3 
fibroblasts,  and endogenous o~PDGFR is  not cross-phos- 
phorylated by the chimeric receptor, our data strongly argue 
that PDGF-induced association of PI-3 kinase activity with 
receptor is not required for aPDGFR-mediated cell growth 
and transformation in a physiologically relevant cell system. 
However,  the exact role of receptor-associated PI-3 kinase 
activity in mediating migration of NIH/3T3 cells remains to 
be established. 
Recently, Kazlauskas et al.  described that an analogous 
double mutant of  human BPDGFR in dog kidney TRMP epi- 
thelial cell can mediate PDGF-induced mitogenic response 
when  expressed  at  high  level  (6  x  106  receptors/cell) 
(Kazlauskas et al., 1992). Since the level of receptor expres- 
sion has been  shown to affect the biological property of 
erbB-2 receptor expressed in NIH/3T3 cells (Di Fiore et al., 
1987b),  it is possible that the mitogenic response mediated 
by double mutant of/3PDGFR was caused by overexpression 
and a physiological level of mutant receptor expression may 
not be sufficient for efficient coupling of receptor to mito- 
genic signaling pathway. However, our data show that a dou- 
ble  mutant  of  c~PDGFR  can  transduce  mitogenic  and 
proliferation signaling, even when expressed at ~5  x  104 
receptors/ceU in both 32D ceils and NIH/3T3 ceils. Since the 
endogenous c~PDGFR is expressed at similar level in fibro- 
blast (see Fig. 5 B and Heidaran et al.,  1993),  our results 
suggest that PDGF-induced PI-3 kinase activity is not re- 
quired for mitogenic signaling, even when the mutant recep- 
tor is expressed at a physiologically relevant level. 
The ligand-dependent activation of  c-rafand ras have been 
shown to be essential for PDGFR-mediated biological re- 
sponse in NIH/3T3 cells (Kolch et al., 1991; Cantley et al., 
1991). Moreover, MAP kinase has also been implicated in 
mitogenic signaling pathways since it has been shown to be 
downstream of raf-1  and to activate c-jun  in the nucleus 
(Kyriakis et al.,  1992;  Howe et al.,  1992;  Pulverer et al., 
1991). Our data showing that mutations of tyrosines 731 and 
742 of otPDGFR did not affect the mobility shift of c-rafand 
tyrosine phosphorylation of MAP kinase suggest this impor- 
tant mitogenic signal pathway to the nucleus is not impaired. 
We  also  found that  activation  of the  wt  c~PDGFR  and 
Y731F/Y742F led to a similar level of tyrosine phosphoryla- 
tion of Shc molecule in 32D cells (data not shown). Shc has 
recently been shown to be involved in mediating ms activa- 
tion in v-src transformed cells (Rozakis-Adcock et al., 1993; 
Egan et al.,  1993).  Thus, our findings also imply that the 
double mutation may not impair the ability of PDGFR to ac- 
tivate ras protein in vivo. These findings are consistent with 
results published recently by Valius  and Kazlauskas, who 
reported characterization of a mutant ~PDGFR that did not 
associate with PI-3 kinase, but was still capable of activating 
ras upon PDGF triggering (Valius and Kazlauskas, 1993). 
Together, all of these data suggest that abrogation of PI-3 ki- 
nase association does not block the critical mitogenic signal- 
ing pathways in vivo. 
The ligand-dependent receptor association and/or tyrosine 
phosphorylation of GAP (Kazlauskas et al., 1992) or PLC3, 
(Valius et al., 1993) have recently been shown to be dispensi- 
ble for PDGF mitogenic signaling in vivo.  Our present re- 
port also suggests that PI-3 kinase association is not required 
for PDGF-stimulated mitogenic signaling. Thus, all of these 
findings suggest that it is possible that any one signal mole- 
cule  can  be  dispensible  for  mitogenic  signaling  due  to 
sufficient redundancy.  Alternatively, these  results  suggest 
that none of these molecules are directly involved in mito- 
genic  pathways,  and  they may  have  functions yet to  be 
identified. In this regard, the sequence homology between 
the pll0 catalytic subunit of PI-3 kinase and a yeast protein 
VPS34 suggest PI-3 kinase may play a protein-sorting func- 
tion in mammalian cells as in yeast (Hiles et al., 1992; Her- 
man and Emr,  1990).  Future investigation of downstream 
signal molecules of PI-3 kinase and the biological function 
of its products should allow us to further dissect the role of 
this enzyme in vivo. 
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